Goldberg Ronald B
Division of Endocrinology, Diabetes, and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33101, USA.
J Clin Endocrinol Metab. 2009 Sep;94(9):3171-82. doi: 10.1210/jc.2008-2534. Epub 2009 Jun 9.
Recent developments indicate that pathophysiological mechanisms leading to beta-cell damage, insulin resistance, and the vascular complications of diabetes include an activation of the inflammation cascade, endothelial dysfunction, and procoagulant imbalance. Their circulating biomarkers may therefore provide opportunities for early diagnosis and targets for novel treatments.
Circulating biomarkers of these pathways such as TNFalpha, IL-6, C-reactive protein (CRP) (inflammation), vascular cellular adhesion molecule-1, interstitial cellular adhesion molecule-1, E-selectin, von Willebrand factor (endothelial dysfunction), plasminogen activator inhibitor-1, fibrinogen, P-selectin (procoagulant state), and adiponectin (antiinflammation) may be associated with development of both type 1 and type 2 diabetes and some studies, particularly in type 2 diabetes, have demonstrated that certain biomarkers may have independent predictive value. Similarly studies have shown that these biomarkers may be associated with development of diabetic nephropathy and retinopathy, and again, particularly in type 2 diabetes, with cardiovascular events as well. Finally, the comorbidities of diabetes, namely obesity, insulin resistance, hyperglycemia, hypertension and dyslipidemia collectively aggravate these processes while antihyperglycemic interventions tend to ameliorate them.
Increased CRP, IL-6, and TNFalpha, and especially interstitial cellular adhesion molecule-1, vascular cellular adhesion molecule-1, and E-selectin are associated with nephropathy, retinopathy, and cardiovascular disease in both type 1 and type 2 diabetes. Whereas further work is needed, it seems clear that these biomarkers are predictors of increasing morbidity in prediabetic and diabetic subjects and should be the focus of work testing their clinical utility to identify high-risk individuals as well as perhaps to target interventions.
最近的研究进展表明,导致β细胞损伤、胰岛素抵抗及糖尿病血管并发症的病理生理机制包括炎症级联反应激活、内皮功能障碍和凝血失衡。因此,它们的循环生物标志物可能为早期诊断提供机会,并成为新型治疗的靶点。
这些通路的循环生物标志物,如肿瘤坏死因子α、白细胞介素-6、C反应蛋白(CRP)(炎症)、血管细胞黏附分子-1、细胞间黏附分子-1、E选择素、血管性血友病因子(内皮功能障碍)、纤溶酶原激活物抑制剂-1、纤维蛋白原、P选择素(凝血状态)和脂联素(抗炎),可能与1型和2型糖尿病的发生发展相关。一些研究,尤其是在2型糖尿病中,已经证明某些生物标志物可能具有独立的预测价值。同样,研究表明这些生物标志物可能与糖尿病肾病和视网膜病变的发生发展相关,而且,同样特别是在2型糖尿病中,也与心血管事件相关。最后,糖尿病的合并症,即肥胖、胰岛素抵抗、高血糖、高血压和血脂异常,共同加剧了这些过程,而降糖干预措施往往会改善这些情况。
CRP、白细胞介素-6和肿瘤坏死因子α升高,尤其是细胞间黏附分子-1、血管细胞黏附分子-1和E选择素升高,与1型和2型糖尿病的肾病、视网膜病变和心血管疾病相关。虽然还需要进一步的研究,但很明显,这些生物标志物是糖尿病前期和糖尿病患者发病风险增加的预测指标,应该成为测试其临床效用以识别高危个体以及可能作为干预靶点的研究重点。